EDP Biotech and New Day Diagnostics announced their combination, forming a vertically integrated force in the expedited development and commercialization of diagnostic tests.
EDP Biotech Corp. currently develops ColoPlex, an aid in diagnosis for detecting colorectal cancers and polyps early, as well as serves a growing roster of diagnostic companies with its full-service CRO focused on In-Vitro Diagnostics (IVD), development, testing, and commercialization, and operates a CLIA lab providing Business-to-Business (B2B) and Direct-to-Consumer (DTC) testing, multiplex assays, research, and validation services.
The Boca Raton-based New Day Diagnostics brings a diversified pipeline of physician Point-of-Care (POC) and Physician Mediated-Direct-to-Consumer (DTC) tests to the combined entity. These include a first-to-market DTC celiac disease test and additional offerings targeting infectious diseases, ovarian cancer, and prostate cancer.
Together, EDP Biotech and New Day Diagnostics are set to capitalize on the changing patient dynamics in the diagnostics industry. By leveraging their combined development capabilities, distribution channels, and strategic partnerships, the merged entity will have the ability to address multiple indications, transforming the way patients access and benefit from diagnostic testing.
The newly merged entity will retain the name New Day Diagnostics, and both companies' teams will unite under a unified leadership structure headquartered in Knoxville, TN. The merger is subject to customary closing conditions and regulatory approvals.
